[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-358694-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-358694-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluating-the-prognostic-significance-of-hist1h4c-in-breast-cancer-implications-for-neoadjuvant-therapy","Evaluating the prognostic significance of HIST1H4C in breast cancer - implications for neoadjuvant therapy","","Evaluating tissue HIST1H4C expression in breast cancer, this study examines whether HIST1H4C levels relate to disease progression and the effectiveness of neoadjuvant therapy. Tissue HIST1H4C mRNA was quantified by qPCR in 105 patients receiving neoadjuvant therapy (2019–2022). High expression before therapy correlated with good responders, whereas high expression after therapy correlated negatively, and expression decreased in good responders. HIST1H4C also associated with ER/PR negativity, high KI67, higher histological grade, larger tumors, and increased lymph node metastasis, indicating a biomarker role for prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-the-prognostic-significance-of-hist1h4c-in-breast-cancer-implications-for-neoadjuvant-therapy/358694/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-the-prognostic-significance-of-hist1h4c-in-breast-cancer-implications-for-neoadjuvant-therapy/358694.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of evaluating HIST1H4C in breast cancer?","Question",{"text":63,"@type":64},"The study investigates tissue HIST1H4C expression and its role in disease progression, including how it interacts with neoadjuvant therapy efficacy and overall prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was HIST1H4C expression measured and in which patients?",{"text":68,"@type":64},"HIST1H4C mRNA was analyzed by qPCR in breast cancer tissue samples from 105 patients who received neoadjuvant therapy between 2019 and 2022.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship did HIST1H4C show with response to neoadjuvant therapy?",{"text":72,"@type":64},"High HIST1H4C before therapy was positively related to good responders (CR+PR), while high HIST1H4C after therapy was negatively related to good responders, with HIST1H4C significantly decreased in good responders.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},358694,1790694392,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEvaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy  \nLi Qian1,2,7, Rui Ge3,7, Zhong Haihu1,2,7, Zhu Cairong1,2, Cai Yuanxuan1,2, Liao Yongdong1,2, Zhu Xiaofeng1,2, Li jingjing1,2, Ye Xuan1,2, Chen Kai4,5􀀍 & Li Jie1,2,6􀀍  \nBreast cancer is a common and highly malignant, currently, HIST1H4C was found to be associated with several human malignancies. The purpose of this study is to investigate tissue HIST1H4C expression in breast cancer and explore its role in disease progression and its interaction with neoadjuvant therapy efficacy. we analyzed tissue HIST1H4C mRNA expression in BC tissue samples from 105 patients received with neoadjuvant therapy using qPCR between 2019 and 2022. Statistical analysis showed that a high expression of HIST1H4C before neoadjuvant therapy was positively related to good responder (CR + PR), while high expression of HIST1H4C after neoadjuvant therapy was negatively related good responder. And HIST1H4C expression was significantly decreased in patients with good responder. In addition, high HIST1H4C expression was also related to ER negative, PR negative, high KI67 expression, high level of histological grade, large tumor size and more lymph node metastases in Curtis database. Furthermore, high HIST1H4C expression before and after-treatment in our center orin database has a positively correlation with poor prognosis. HIST1H4C is the potential biomarker of neoadjuvant therapy and prognosis for breast cancer.  \nKeywords HIST1H4C, Neoadjuvant therapy efficacy, Prognosis, BC  \nBreast cancer (BC) is the most common malignant tumor in women worldwide1. Chemotherapy plays a crucial role in the systemic treatment of breast cancer, with neoadjuvant chemotherapy (NACT) being particularly important. NACT aims to shrink tumor size before surgery, making inoperable breast cancer operable and improving surgical success rates. It also provides valuable information on drug sensitivity and guides subsequent treatment2. Studies have shown that NACT can improve prognosis, increase the rate of pathological complete response (pCR), and enhance event-free survival (EFS) in breast cancer patients3–5.  \nIn 2014, the CTNeoBC study validated that achieving pCR following NACT was associated with a more favorable prognosis6. The I-SPY2 study further confirmed that hormone receptor (HR) -positive breast cancer patients who achieved pCR had significantly prolonged survival7. However, a significant number of HR-positive breast cancer patients exhibit chemotherapy resistance, and NACT may lead to an inadequate tumor shrinkage or downstaging and unexpected and irreversible adverse reactions. Therefore, identifying patients who benefit most from NACT and tailoring personalized treatment strategies is crucial.  \nTumor heterogeneity is reflected in tumor pathology grade8, various classification systems are used globally, with the Histological Classification System (HCS) being one of the most widely recognized. Histologically, the malignancy level of breast cancer is closely associated with its grade, which correlates with the proliferation index and DNA ploidy9. As a result, this index holds considerable significance in assessing the differentiation level and prognosis of breast cancer9, 10. Invasive ductal carcinoma, in particular, exhibited significantly more responsiveness to chemotherapy compared to non-invasive ductal carcinoma, and treatment approaches  \n1Thyroid and Breast Department, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China. 2Institute of Reproductive Health and Perinatology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9\\# Jinsui Road, Guangzhou 510655, China. 3Huadong Hospital Affiliated to Fudan University, Shanghai, China. 4Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation","cbCaiu400Z4x6g4T","https://ap.wps.com/l/cbCaiu400Z4x6g4T","pdf",3396643,"English","# Background\n## Neoadjuvant chemotherapy and prognosis\n## Tumor grade and histological classification\n# Methods\n## mRNA extraction and qPCR\n## Single-cell sequencing datasets\n# Results\n## Association with therapy response\n## Association with clinical and molecular features\n## Prognostic correlation","[{\"question\":\"What is the main purpose of evaluating HIST1H4C in breast cancer?\",\"answer\":\"The study investigates tissue HIST1H4C expression and its role in disease progression, including how it interacts with neoadjuvant therapy efficacy and overall prognosis.\"},{\"question\":\"How was HIST1H4C expression measured and in which patients?\",\"answer\":\"HIST1H4C mRNA was analyzed by qPCR in breast cancer tissue samples from 105 patients who received neoadjuvant therapy between 2019 and 2022.\"},{\"question\":\"What relationship did HIST1H4C show with response to neoadjuvant therapy?\",\"answer\":\"High HIST1H4C before therapy was positively related to good responders (CR+PR), while high HIST1H4C after therapy was negatively related to good responders, with HIST1H4C significantly decreased in good responders.\"}]","Evaluating the prognostic significance of HIST1H4C in breast cancer - implications for neoadjuvant therapy | PDF",1790135001,23]